4D Molecular Therapeutics FDMT Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's total liabilities & equity?
- 4D Molecular Therapeutics (FDMT) reported total liabilities & equity of $512.91M in Q1 2026.
- How has 4D Molecular Therapeutics's total liabilities & equity changed year-over-year?
- 4D Molecular Therapeutics's total liabilities & equity decreased by 0.5% year-over-year, from $515.73M to $512.91M.
- What is the long-term trend for 4D Molecular Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's total liabilities & equity has grown at a 14.5% compound annual growth rate (CAGR), from $288.33M to $566.71M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.